Abeona Therapeutics Inc vs Bandwidth Inc — how do they compare? Abeona Therapeutics Inc trades at $7.4 (market cap $421.19M), while Bandwidth Inc trades at $51.42 (market cap $1.66B). The key difference: Bandwidth Inc is far larger — about 3.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Bandwidth Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | BAND | |
|---|---|---|
Market Cap | $421.19M | $1.66B |
Sector | Health | Technology |
52-Week High | $7.45 | $78.44 |
52-Week Low | $4.17 | $12.82 |
Enterprise Value | $276.10M | $2.04B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.46, up 0.13% with strong technical momentum as moving averages signal bullish sentiment. The company shows exceptional profitability with 454.86% net income margin and 70.99% ROE, though revenue remains modest at $5.82M. Recent positive developments include CMS granting NTAP status for ZEVASKYN and expanding treatment centers, while consistently beating earnings expectations.
Outlook remains positive with analyst consensus at 66.7% buy ratings, but risks include shareholder investigation and high RSI levels suggesting overbought conditions. The stock's valuation appears reasonable with P/E of 7.78, though negative operating cash flow requires monitoring as the company scales commercialization efforts.
Bandwidth (BAND) trades at $51.97, down 1.4% over 24 hours, with a bullish technical outlook supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 results, beating EPS estimates with $0.37 versus $0.3652 expected, and raised its full-year outlook on AI-driven demand growth. Revenue climbed 22% year-over-year to $220 million, though net income margins remain thin at 0.27% for 2026.
The stock offers upside to the $75.25 analyst consensus target, fueled by AI adoption and enterprise wins, but risks include high valuation multiples like a 34.08 EV/EBITDA and competitive pressures in cloud communications. Execution on profitability improvements will be critical for sustaining gains.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →Bandwidth is a global communications software company. Its CPaaS platform allows enterprises to embed voice, messaging, and 911 emergency services directly into their software applications via robust APIs.
Read more on BAND →